Lateral pelvic lymph nodes (LPLN) in mid-/low rectal cancer pose a theoretical and practical challenge for the clinician and the patient, with geographical differences in management based on historical competing priorities. Although there has been a tendency to think of neoadjuvant radiation versus intraoperative LPLN dissection as a binary choice, they should be more constructively seen as complementary options in the personalized management of patients with rectal cancer. Herein we propose one potential algorithm for using these treatment options in this way based on local preoperative staging and the current evidence available. We also outline future research priorities in this area with the aim of answering several residual questions that remain. has, to some extent, however, taken the attention away from the importance of surgical clearance of pelvic lymph node metastases, so much so that many surgeons in the West still consider positive lateral nodes to be systemic/distant disease, rather than locoregional disease. Anatomically and biologically, it is more appropriate to consider lateral nodes for a tumor in the mid-and low rectum as locoregional, rather than as distant disease. In the East, the evolution in gastrointestinal cancer surgery in general has been toward lymph
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K E Y W O R D S
chemoradiotherapy for rectal cancer, lateral pelvic lymph node, lateral pelvic lymph node dissection, multidisciplinary treatment for rectal cancer, rectal cancer Management of lateral pelvic lymph nodes (LPLN) in rectal cancer poses theoretical and practical challenges, with ongoing debate and interest regarding the respective roles of dissection and neoadjuvant radiation treatment in this setting. 1 In the West, the paradigm for rectal cancer management is well established. Broadly speaking, early disease is treated with total mesorectal excision (TME) alone, but for more advanced disease (with significant adenopathy or a threatened radial margin) neoadjuvant therapy is used. In selected cases, induction chemotherapy or consolidation chemotherapy may also be used, all before carrying out surgery. 2, 3 The paradigm in some Eastern countries differs somewhat. In Japan, according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines, Ra (above the peritoneal reflection) rectal cancer is treated by surgery and adjuvant chemotherapy for node-positive disease and, for Rb (below the peritoneal reflection) tumors, lateral pelvic lymph node dissection is carried out as part of the routine surgical treatment. 4 Western centers do not routinely remove the LPLN for early or advanced disease, instead focusing on neoadjuvant treatment as the mainstay of treatment for the lateral compartment.
These differing paradigms have developed out of competing priorities. In the West, the main focus has been oncological surgical clearance of the resection margin. The circumferential resection margin (CRM) is one of the most important prognostic factors in rectal cancer surgery with respect to local control and therefore deserves considerable attention. This is particularly true considering the high local recurrence rates reported in early surgical series. 5 This focus has, to some extent, however, taken the attention away from the importance of surgical clearance of pelvic lymph node metastases, so much so that many surgeons in the West still consider positive lateral nodes to be systemic/distant disease, rather than locoregional disease. Anatomically and biologically, it is more appropriate to consider lateral nodes for a tumor in the mid-and low rectum as locoregional, rather than as distant disease. In the East, the evolution in gastrointestinal cancer surgery in general has been toward lymph
node clearance and, as a result, lateral pelvic nodes have been considered local-regional disease from the outset. The treatment has thus evolved to include surgical therapy of this compartment for patients with rectal cancer. Conversely, neoadjuvant chemoradiation to improve margin control has received relatively less attention.
Multiple randomized trials in the West have confirmed that neoadjuvant treatment improves local control. [6] [7] [8] Conversely, several studies from Japan have also demonstrated good local control with LPLN dissection without neoadjuvant treatment. 9 The recently published JCOG0212 trial compared routine LPLN dissection versus TME alone in patients without clinical evidence of LPLN metastasis. 10 The rate of local recurrence with LPLN dissection was lower than without routine dissection and, therefore, the non-inferiority of TME alone in patients without clinical evidence of LPLN metastasis was not proven. This suggests that, at least in the Japanese population, lateral node dissection can be used to reduce local recurrence in the absence of neoadjuvant radiation. Several years ago, data from the Dutch TME trial were compared directly with data from the National Cancer Center Hospital. 11 The rates of local control were again not different between TME preceded by radiotherapy versus TME with lateral pelvic lymph node dissection (with the caveat that in the Dutch TME trial, the rate of radial margin positivity for distal disease was unacceptably high at more than 20%). A 2009 meta-analysis also showed no difference in local recurrence, overall or disease-free survival between "extended lymphadenectomy" including the lateral compartment versus neoadjuvant treatment without extended lymphadenectomy. 12 Increased rates of male sexual and urinary dysfunction were noted in the lymphadenectomy group, but this was not supported by the more recent JCOG0212 data.
12,13
Despite ongoing attempts to compare radiation with LPLN dissection, in the authors' opinion, it is not correct (nor constructive)
to think about lateral compartment management as a simplified binary choice. 14 It is clear that even in the context of neoadjuvant treatment, LPLN abnormalities detected on pretreatment imaging do still matter. 15 Data from a Korean study which included patients who underwent chemoradiation therapy and then TME without lateral lymph node dissection showed on multivariate analysis that LPLN short-axis diameter (<5, 5-10, and ≥10 mm) was significantly associated with locoregional recurrence-free survival, relapse-free survival, and overall survival. 16 Japanese data would suggest a cutoff of 8 mm is independently predictive of residual nodal disease after chemoradiation. 17 Response to neoadjuvant treatment also has a role to play, with poor responders in the lateral compartment having demonstrably worse oncological outcomes and potentially more to gain from dissection after neoadjuvant treatment. [18] [19] [20] Recurrence and survival benefit from posttreatment dissection has yet to be confirmed in this context, however.
14 Based on the available information, we would suggest that patients with mid-/low rectal cancer being treated with curative intent could be classified into three categories for the purposes of the lateral compartment management:
1. Low risk of LPLN disease, defined as: cT1/T2/early T3 (and Ra) with clinically negative LPLN on MRI.
2. Moderate risk of LPLN disease, defined as: cT3 + /T4 with clinically negative LPLN on MRI (potential microscopic disease) (or Rb).
3. High risk of LPLN disease, defined as clinically abnormal LPLN on MRI (macroscopic disease) (Ra or Rb).
Broadly speaking and pending further evidence, the authors would argue that patients in group 1 could be managed with TME surgery alone, patients in group 2 with neoadjuvant treatment + TME or TME + LPLN dissection, and group 3 with neoadju- 
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